LOEs

cagkansayin With Big Pharma $380B deal-making firepower, Morgan Stanley cites a favorable backdrop for biopharma M&A as key drugs in their portfolios face patent cliffs, risking as much as $180B in revenue. In a research note this week, Morgan Stanley analysts led by Terence Flynn listed large-cap drugmakers with theContinue Reading